Titlebook: Difficult Decisions in Thoracic Surgery; An Evidence-Based Ap Mark K. Ferguson (Professor and Head) Book 20071st edition Springer-Verlag Lo

不如屎殼郎

deactivate

Induction Therapy for Stage IIIA (N2) Lung Cancerion of patients into potentially resectable and unresectable categories. This dividing line was set between stage IIIA and stage IIIB disease with contralateral lymph node metastases or local involvement of unresectable or marginally resectable structures defining the limits of surgical treatment. t

文字

Adjuvant Postoperative Therapy for Completely Resected Stage I Lung Cancerservational studies shows that surgery offers patients the highest cure rate. Nevertheless, following lobectomy or pneumonectomy and mediastinal lymph node staging as standard therapy, only a 67% 5-year survival for stage IA (T1N0) and a 57% 5-year survival for stage IB (T2N0) is expected, with most

conservative

Sleeve Lobectomy Versus Pneumonectomy for Lung Cancer Patients with Good Pulmonary Functionmanagement of centrally located tumors. Initially, surgical therapy of central tumors consisted of pneumonectomy as the only surgical option with favorable outcomes. However, parenchymalsparing procedures, such as sleeve lobectomy, were subsequently described for patients unable to tolerate pneumone

conscience

一夫一妻制

Lesser Resection Versus Radiotherapy for Patients with Compromised Lung Function and Stage I Lung Cafortunately, a substantial subset of patients diagnosed with early-stage NSCLC suffer from cardiopulmonary disease and/or other underlying medical comorbidities, and therefore are not suitable candidates for standard therapy. Treatment options for patients unable to tolerate lobectomy are typically

絕食

Resection for Patients Initially Diagnosed with N3 Lung Cancer after Response to Induction Therapyes are present at the time of diagnosis. N3 lung tumors have been included in stage IIIB since 1986, when it appeared clear that such locally advanced disease needs to be grouped in a separate stage III category because of the extremely poor prognosis. In the large series reported by Mountain, 5-yea

驚呼

玉米

Surgery for Non-Small Cell Lung Cancer with Solitary M1 Diseaseis chemotherapy or palliative care. A small percentage of patients with newly diagnosed and untreated stage IV disease are found to have a solitary synchronous site of extrathoracic disease, and a small number of patients who have undergone curative resections of intrathoracic disease experience met

misanthrope

Induction Therapy for Stage IIIA (N2) Lung Cancerreatment. The advent of modern cancer therapy with multimodality approaches including surgery, chemotherapy, and radiation therapy has raised significant questions that are still not completely resolved as to the best approach for patients with potentially resectable stage IIIA (N2) disease at presentation.